Literature DB >> 25989199

Histoplasmosis in Idaho and Montana, USA, 2012-2013.

Randall J Nett, Donald Skillman, Laurel Riek, Brian Davis, Sky R Blue, Elizabeth E Sundberg, Joel R Merriman, Christine G Hahn, Benjamin J Park.   

Abstract

Entities:  

Keywords:  Histoplasma capsulatum; Idaho; Montana; United States; endemic diseases; fungi; histoplasmosis; mycoses

Mesh:

Year:  2015        PMID: 25989199      PMCID: PMC4451912          DOI: 10.3201/eid2106.141367

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Histoplasmosis occurs after infection with the dimorphic fungus Histoplasma capsulatum (–). Patients become ill after they inhale soil contaminated with H. capsulatum (,). Most infections are asymptomatic or result in mild illness not determined to be histoplasmosis (,). Symptoms usually develop 3–14 days after exposure and range from self-limited pneumonia to severe disseminated disease requiring antifungal therapy (,). In the United States, H. capsulatum is endemic to the Mississippi and Ohio River Valleys (,,,) but is not known to be endemic to the Rocky Mountain region (). During June 2012–November 2013, a total of 6 unrelated cases of histoplasmosis were reported in Idaho (n = 1) and Montana (n = 5) in patients who had no recent travel to recognized H. capsulatum–endemic regions. Public health authorities investigated the illnesses by reviewing medical records and collecting exposure and travel histories. The median age of the patients (3 male, 3 female) was 68 (range 17–79) years (Table). Each case was diagnosed by a different physician; no known epidemiologic links existed among the patients. Five patients had >1 immunocompromising conditions (Table), and 2 had acute pneumonia; 1 each had left parotid gland enlargement, anterior cervical lymphadenopathy, tricuspid valve mass, and acute changes in mental status. Three patients were hospitalized: 2 required intensive care, and 1 died.
Table

Characteristics of 6 persons with histoplasmosis, Idaho and Montana, USA, 2012–2013*

CharacteristicValue
Sex
M 3 (50)
F
3 (50)
Median age, y (range)
68 (17–79)
Location of residence
Idaho, southwestern1 (17)
Montana
Eastern2 (33)
Southwestern
3 (50)
Immunocompromising condition, n = 5†
Diabetes mellitus, type 23 (50)
Hepatitis C1 (17)
Previous history of breast cancer1 (17)
Acute mononucleosis1 (17)
Previous history of colon cancer
1 (17)
Hospitalization3 (50)
Death
1 (17)
Tests with positive results that contributed to histoplasmosis diagnosis
Culture2 (33)
Histopathology‡2 (33)
Urine enzyme immunoassay‡2 (33)
Diagnosis delayed >6 mo
3 (50)
At-risk activities
Using potting soil containing bat guano 1 (17)
Exploring caves1 (17)
Mowing grass in pasture1 (17)
Cleaning pigeon cages1 (17)
Traveling to an area where the disease is endemic <3 y of illness onset0
None known2 (33)

*Values are no. (%) patients except as indicated.
†One patient had diabetes mellitus type 2 and hepatitis C; 1 patient had diabetes mellitus type 2 and a previous history of colon cancer.
‡One patient with a culture positive for Histoplasma capsulatum also had histopathology and urine enzyme immunoassay results consistent with H. capsulatum infection (results not shown).

*Values are no. (%) patients except as indicated.
†One patient had diabetes mellitus type 2 and hepatitis C; 1 patient had diabetes mellitus type 2 and a previous history of colon cancer.
‡One patient with a culture positive for Histoplasma capsulatum also had histopathology and urine enzyme immunoassay results consistent with H. capsulatum infection (results not shown). Histoplasmosis was diagnosed primarily on the basis of culture (n = 2), urine enzyme immunoassay (EIA) (n = 2), and histopathologic examination (n = 2) results; histopathologic examinations were conducted by 2 pathologists (Technical Appendix Table). One patient with H. capsulatum–positive cultures also had positive results by histopathology, serum antigen detection, and urine EIA. Another patient with positive urine EIA results for antigen detection also had low serum levels of Histoplasma antibodies measured by compliment fixation. No patient samples were tested by PCR. The interval between a patient’s initial visit to a health care provider and diagnosis ranged from 1 week to 20 months. Diagnosis was delayed >6 months for 3 patients. For 2 patients, a diagnosis was made on the basis of an H. capsulatum–positive urine EIA result <4 weeks from illness onset. Four (67%) patients underwent surgical procedures before histoplasmosis was diagnosed. Each patient reported having traveled to H. capsulatum–endemic places, but none had traveled to these areas within 3 years of illness onset. Four patients reported exposures possibly related to infection (1 patient each): handling bat guano–containing potting soil manufactured in California, exploring caves, mowing pasture grass, and cleaning pigeon cages. The exposure to potting soil occurred in California; the other 3 exposures occurred in Montana. Two patients had no identifiable high-risk exposures to H. capsulatum. These 6 patients with histoplasmosis represent potential acute infections and suggest that H. capsulatum might exist in Idaho and Montana, a geographic area farther west than areas where the fungus is known to be endemic. Areas of contaminated soils exist in microfoci outside recognized H. capsulatum–endemic areas and can be the source of infection for some persons (). Previous studies suggest that the H. capsulatum–endemic area might extend into Montana and possibly other states in the Rocky Mountain region (–). Further environmental studies are needed to determine with certainty whether H. capsulatum fungi exist in natural environments in the Rocky Mountain region. Delayed diagnosis of histoplasmosis increases the likelihood of delays in administering effective antifungal therapy. Histoplasmosis was diagnosed in 3 of these patients >6 months after they first sought care, probably because they had reported no recent travel to H. capsulatum–endemic areas. Among these 3 patients, none had urine EIA testing for the presence of H. capsulatum antigen. The 2 patients who received a diagnosis of histoplasmosis <4 weeks after they first sought care were assessed by using urine EIA. Urine EIA is a noninvasive and sensitive assay with high specificity but is subject to false-positive results in patients with other fungal infections, particularly blastomycosis (), which is not known to be endemic in Montana or Idaho. Investigation of these 6 histoplasmosis cases was limited because only 2 patients had cultures positive for H. capsulatum, and each patient had a remote travel history (>3 years before infection) to an H. capsulatum–endemic area. These limitations raise the possibility that the cases represent reactivation of latent disease or delayed clinical manifestations following a low-inoculum exposure years earlier in an area where the fungus is endemic (,). However, data supporting the possibility that reactivation of latent H. capsulatum infection causes acute illness are inconclusive (). In summary, health care providers should consider a diagnosis of histoplasmosis for Idaho and Montana residents having symptoms consistent with the disease, regardless of whether they have a travel history to recognized H. capsulatum–endemic areas. When considering a diagnosis of histoplasmosis, providers should also consider testing with urine EIA, a noninvasive way to assess the presence of H. capsulatum infection. Technical Appendix. Laboratory findings in histoplasmosis patients, Idaho and Montana, USA, 2012–2013.
  10 in total

Review 1.  Pulmonary histoplasmosis.

Authors:  David S McKinsey; Joel P McKinsey
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

Review 2.  Histoplasmosis: a clinical and laboratory update.

Authors:  Carol A Kauffman
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 3.  Histoplasmosis.

Authors:  Carol A Kauffman
Journal:  Clin Chest Med       Date:  2009-06       Impact factor: 2.878

4.  An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States.

Authors:  L B Edwards; F A Acquaviva; V T Livesay; F W Cross; C E Palmer
Journal:  Am Rev Respir Dis       Date:  1969-04

Review 5.  Histoplasmosis: a review for clinicians from non-endemic areas.

Authors:  L Joseph Wheat
Journal:  Mycoses       Date:  2006-07       Impact factor: 4.377

Review 6.  Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis.

Authors:  Carol A Kauffman
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

Review 7.  Pulmonary fungal infections.

Authors:  Jeannina A Smith; Carol A Kauffman
Journal:  Respirology       Date:  2012-08       Impact factor: 6.424

8.  Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America.

Authors:  L Joseph Wheat; Alison G Freifeld; Martin B Kleiman; John W Baddley; David S McKinsey; James E Loyd; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2007-08-27       Impact factor: 9.079

9.  Hospitalizations for endemic mycoses: a population-based national study.

Authors:  Jaclyn H Chu; Chris Feudtner; Kateri Heydon; Thomas J Walsh; Theoklis E Zaoutis
Journal:  Clin Infect Dis       Date:  2006-02-01       Impact factor: 9.079

10.  Geographic distribution of endemic fungal infections among older persons, United States.

Authors:  John W Baddley; Kevin L Winthrop; Nivedita M Patkar; Elizabeth Delzell; Timothy Beukelman; Fenglong Xie; Lang Chen; Jeffrey R Curtis
Journal:  Emerg Infect Dis       Date:  2011-09       Impact factor: 6.883

  10 in total
  6 in total

Review 1.  Mycotic Infections Acquired outside Areas of Known Endemicity, United States.

Authors:  Kaitlin Benedict; George R Thompson; Stan Deresinski; Tom Chiller
Journal:  Emerg Infect Dis       Date:  2015-11       Impact factor: 6.883

Review 2.  Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens.

Authors:  Daniel Z P Friedman; Ilan S Schwartz
Journal:  J Fungi (Basel)       Date:  2019-07-20

3.  Histoplasmosis in an elderly polish tourist - a case report.

Authors:  Krzysztof Specjalski; Karolina Kita; Krzysztof Kuziemski; Beata Tokarska; Lucyna Górska; Jolanta Szade; Alicja Siemińska; Marta Chełmińska; Ewa Jassem
Journal:  BMC Pulm Med       Date:  2019-08-14       Impact factor: 3.317

Review 4.  The Consequences of Our Changing Environment on Life Threatening and Debilitating Fungal Diseases in Humans.

Authors:  Norman van Rhijn; Michael Bromley
Journal:  J Fungi (Basel)       Date:  2021-05-07

5.  Mapping Histoplasma capsulatum Exposure, United States.

Authors:  Amelia W Maiga; Stephen Deppen; Beth Koontz Scaffidi; John Baddley; Melinda C Aldrich; Robert S Dittus; Eric L Grogan
Journal:  Emerg Infect Dis       Date:  2018-10       Impact factor: 6.883

Review 6.  Re-drawing the Maps for Endemic Mycoses.

Authors:  Nida Ashraf; Ryan C Kubat; Victoria Poplin; Antoine A Adenis; David W Denning; Laura Wright; Orion McCotter; Ilan S Schwartz; Brendan R Jackson; Tom Chiller; Nathan C Bahr
Journal:  Mycopathologia       Date:  2020-02-10       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.